Table 2 Prognostic comparison of the different treatment regimens received within 4.5 h of stroke onset among the enrolled patients

CHADS2 score, M (IQR)

4.00 (3.00, 4.00)

3.00 (3.00, 4.00)

3.00 (3.00, 4.00)

4.00 (3.00, 4.00)

0.005

CHA2DS2-VASc score, M (IQR)

5.00 (4.00, 6.00)

5.00 (4.00, 6.00)

5.00 (4.00, 6.00)

5.00 (5.00, 6.00)

< 0.001

HAS-BLED score, M (IQR)

3.00 (3.00, 4.00)

3.00 (3.00, 4.00)

3.00 (3.00, 4.00)

4.00 (3.00, 4.00)

0.001

HAS-BLED score ≥ 3 points n (%)

289 (86.27)

66 (84.62)

74 (84.09)

149 (88.17)

0.594

NIHSS score before treatment, M (IQR)

10.00 (4.00, 15.00)

14.00 (10.00, 19.00)

9.50 (3.00, 13.00)

8.00 (3.00, 15.00)

< 0.001

NIHSS score after 1-week of treatment, M (IQR)

7.00 (2.00, 14.00)

9.00 (3.00, 17.00)

6.00 (1.25, 12.00)

6.00 (2.00, 14.00)

0.059

Reduction in NIHSS score, M (IQR)

1.00 (0.00, 3.00)

3.00 (1.00, 9.00)

1.00 (0.00, 3.00)

1.00 (0.00, 2.00)

< 0.001

Intracranial haemorrhage transformation, n (%)

26 (7.8)

13 (16.7)

4 (4.5)

9 (5.3)

0.003

Extracranial haemorrhage transformation, n (%)

4 (1.2)

2 (2.6)

0 (0.0)

2 (1.2)

0.316

Antiplatelet prophylaxis, n (%)

109 (32.5)

10 (12.8)

25 (28.4)

74 (43.8)

< 0.001

insufficient to regulate secondary prevention, n (%)

167 (49.9)

54 (69.2)

32 (36.4)

81 (47.9)

< 0.001

3-month mRS, M (IQR)

3.00 (1.00, 5.00)

3.00 (1.00, 5.00)

2.00 (1.00, 4.00)

3.00 (1.00, 5.00)

0.096

Within-3-month mRS ≤ 2 points n (%)

164 (49.0)

30 (38.5)

53 (60.2)

81 (47.9)

0.018

Death within 3 months, n (%)

63 (18.8)

16 (20.5)

11 (12.5)

36 (21.3)

0.209